Will Ziopharm’s Positive Tests Impress These Top Institutional Shareholders?
Ziopharm Oncology (NASDAQ:ZIOP) presented data at the American Association for Cancer Research annual meeting from its study in a breast cancer murine model demonstrating the anti-tumor effects and tolerability of Ad-RTS-mIL-12, a viral vector DNA-based therapeutic for the controlled, local expression of IL-12, an important protein for enhancing antitumor immunity. The study resulted in a dose-related decrease in tumor growth rate. Moreover, the therapeutic strategy appears to be well tolerated, as no change in clinical signs or body weight was observed in the treated animals when compared with vehicle alone.
These institutional firms indicated owning shares of Ziopharm in Q1 2013. They reported owning a total of 0 shares on 03/31/2013. The shares closed at $1.83 on 03/31/2013.
Here are the nine largest positions in Ziopharm at the end of March 31, 2013.
Third Security LLC held 14,939,747 shares on 12/31/2012 worth $62,149,345.
FMR LLC held 10,940,178 shares on 12/31/2012 worth $45,511,139.
Vanguard Group held 3,705,985 shares on 12/31/2012 worth $15,416,897.
Essex Woodlands Health Ventures held 2,764,908 shares on 12/31/2012 worth $11,502,017.
State Street Corp held 2,239,041 shares on 12/31/2012 worth $9,314,410.
Blackrock Fund Advisors held 1,539,215 shares on 12/31/2012 worth $6,403,134.
MSDC Management held 1,150,000 shares on 12/31/2012 worth $4,784,000.
Northern Trust held 969,157 shares on 12/31/2012 worth $4,031,693.
Blackrock Institutional Trust Company held 908,545 shares on 12/31/2012 worth $3,779,547.
Knowing which stocks have institutional support will help improve your investing skills, and teach you how to ride the waves of strong moves. In fact, “S = Support is Provided By Institutional Investors & Company Insiders” is a core component of our CHEAT SHEET investing framework for this very reason. Don’t waste another minute — click here and get our CHEAT SHEET stock picks now.